biostudies-literatureSeiler LKDeutsche ForschungsgemeinschaftGerman Center for Infection Researchstart-up project SU02 and the Core Facility Diagnostic Centre of the IFB-TxEuropean Regional Development Fund308https://www.ebi.ac.uk/biostudies/studies/S-EPMC8871475biostudies-literatureUnknown12(2)Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-meDiagnostics (Basel, Switzerland)An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation.PMC8871475TTU-IICH07.80185006385SFB738-B8ZF4409702 CR83442/7-101EO0802Phung NLLindner PThoms SKaufeld JMayer GNikolin CErck CFalk CSSiegl JHaller HJonczyk RImmenschuh SBlume CAFeederle RSeiler LKfalseAn Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation.Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-me2022-01-01T00:00:00Z2022 Jan2025-04-22T19:05:50.222Z2025-04-06T02:39:52.281ZS-EPMC88714753520439910.3390/diagnostics12020308